---
document_datetime: 2025-12-02 06:11:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/fortacin.html
document_name: fortacin.html
version: success
processing_time: 0.091506
conversion_datetime: 2025-12-23 21:02:45.8629
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Fortacin

[RSS](/en/individual-human-medicine.xml/66252)

##### Authorised

This medicine is authorised for use in the European Union

lidocaine / prilocaine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Fortacin](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Fortacin is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration).

Fortacin contains the active substances lidocaine and prilocaine.

Expand section

Collapse section

## How is Fortacin used?

Fortacin can be obtained without a prescription and is available as a spray-on solution that supplies 7.5 mg of lidocaine and 2.5 mg of prilocaine per spray. The recommended dose is 3 sprays onto the head (glans) of the penis before intercourse. Doses should not be repeated more frequently than every 4 hours, and no more than 3 doses should be used in 24 hours. For more information about using Fortacin, see the package leaflet or contact your doctor or pharmacist.

## How does Fortacin work?

The active substances in the medicine, lidocaine and prilocaine, are local anaesthetics that temporarily numb the contact area by blocking the transmission of signals in the nerves. This reduces sensitivity to stimulation, helping to increase the time taken to ejaculate.

## What benefits of Fortacin have been shown in studies?

The effectiveness of Fortacin has been shown in two main studies involving 256 and 300 heterosexual adult men with premature ejaculation, respectively; both studies compared the medicine with a placebo (dummy) spray over 12 weeks. The main measures of effectiveness were the time taken to ejaculate after penetration and control over ejaculation, sexual satisfaction and distress reported by the patients. In the first study, the average time to ejaculation in patients treated with Fortacin was 2.6 minutes, compared with 0.8 minutes in those using placebo; in the second study, average ejaculation time in patients using the medicine was 3.8 minutes compared with 1.1 minutes in the placebo group. In both studies, patients given the medicine reported substantially greater improvements in reported control, sexual satisfaction and distress than patients given the placebo. Some patients from the main studies were monitored for up to 9 and Fortacin continued to show similar benefit.

## What are the risks associated with Fortacin?

The most common side effects with Fortacin (which may affect up to 1 in 10 people) are hypoaesthesia (reduced sensation) and a burning sensation in the genital area in both men and their sexual partners, and erectile dysfunction (inability to maintain a normal erection) in men. For the full list of side effects with Fortacin, see the package leaflet.

Fortacin must not be used in patients who are hypersensitive (allergic) to other local anaesthetics which are chemically similar with the active ingredients (amide-type local anaesthetics). Fortacin must also not be used in patients whose partners are hypersensitive to these substances. For the full list of restrictions, see the package leaflet.

## Why is Fortacin approved?

The European Medicines Agency considered that the active ingredients are a well-known local anaesthetic combination, and the use of a local spray minimises the amount of active substance absorbed and hence the risk of side effects affecting the body as a whole. There were positive psychological benefits to patients and their partners, and side effects were generally manageable and confined to the area coming into contact with the medicine. The Agency therefore decided that Fortacin's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Fortacin?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fortacin have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Fortacin are continuously monitored. Side effects reported with Fortacin are carefully evaluated and any necessary action taken to protect patients.

## Other information about Fortacin

Lidocaine/Prilocaine Plethora received a marketing authorisation valid throughout the EU on 15 November 2013.

The name of the medicine was changed to Fortacin on 26 September 2014.

Fortacin : EPAR - Medicine overview

Reference Number: EMA/414001/2020

English (EN) (120.28 KB - PDF)

**First published:** 25/11/2013

**Last updated:** 19/10/2020

[View](/en/documents/overview/fortacin-epar-medicine-overview_en.pdf)

Fortacin : EPAR - Risk-management-plan summary

English (EN) (60.74 KB - PDF)

**First published:** 19/10/2020

[View](/en/documents/rmp-summary/fortacin-epar-risk-management-plan-summary_en.pdf)

## Product information

Fortacin : EPAR - Product Information

English (EN) (911.09 KB - PDF)

**First published:** 25/11/2013

**Last updated:** 03/02/2025

[View](/en/documents/product-information/fortacin-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-758)

български (BG) (945.27 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/bg/documents/product-information/fortacin-epar-product-information_bg.pdf)

español (ES) (522.79 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/es/documents/product-information/fortacin-epar-product-information_es.pdf)

čeština (CS) (904.98 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/cs/documents/product-information/fortacin-epar-product-information_cs.pdf)

dansk (DA) (868.88 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/da/documents/product-information/fortacin-epar-product-information_da.pdf)

Deutsch (DE) (448.71 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/de/documents/product-information/fortacin-epar-product-information_de.pdf)

eesti keel (ET) (744.68 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/et/documents/product-information/fortacin-epar-product-information_et.pdf)

ελληνικά (EL) (946.57 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/el/documents/product-information/fortacin-epar-product-information_el.pdf)

français (FR) (880.63 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/fr/documents/product-information/fortacin-epar-product-information_fr.pdf)

hrvatski (HR) (702.06 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/hr/documents/product-information/fortacin-epar-product-information_hr.pdf)

íslenska (IS) (430.89 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/is/documents/product-information/fortacin-epar-product-information_is.pdf)

italiano (IT) (483.91 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/it/documents/product-information/fortacin-epar-product-information_it.pdf)

latviešu valoda (LV) (491.17 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/lv/documents/product-information/fortacin-epar-product-information_lv.pdf)

lietuvių kalba (LT) (509.65 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/lt/documents/product-information/fortacin-epar-product-information_lt.pdf)

magyar (HU) (930.17 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/hu/documents/product-information/fortacin-epar-product-information_hu.pdf)

Malti (MT) (548.69 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/mt/documents/product-information/fortacin-epar-product-information_mt.pdf)

Nederlands (NL) (439.74 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/nl/documents/product-information/fortacin-epar-product-information_nl.pdf)

norsk (NO) (425.16 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/no/documents/product-information/fortacin-epar-product-information_no.pdf)

polski (PL) (530.65 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/pl/documents/product-information/fortacin-epar-product-information_pl.pdf)

português (PT) (463.51 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/pt/documents/product-information/fortacin-epar-product-information_pt.pdf)

română (RO) (609.27 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/ro/documents/product-information/fortacin-epar-product-information_ro.pdf)

slovenčina (SK) (783.15 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/sk/documents/product-information/fortacin-epar-product-information_sk.pdf)

slovenščina (SL) (493.76 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/sl/documents/product-information/fortacin-epar-product-information_sl.pdf)

Suomi (FI) (758.29 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/fi/documents/product-information/fortacin-epar-product-information_fi.pdf)

svenska (SV) (424.22 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

03/02/2025

[View](/sv/documents/product-information/fortacin-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0040 31/01/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Fortacin : EPAR - All Authorised presentations

English (EN) (17.59 KB - PDF)

**First published:** 25/11/2013

**Last updated:** 07/09/2017

[View](/en/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-875)

български (BG) (49.48 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/bg/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.29 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/es/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_es.pdf)

čeština (CS) (32.42 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/cs/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (20 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/da/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (20.46 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/de/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.22 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/et/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (48.97 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/el/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_el.pdf)

français (FR) (17.79 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/fr/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (29.76 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/hr/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (39.48 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/is/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_is.pdf)

italiano (IT) (20.27 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/it/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (47.23 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/lv/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (53.8 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/lt/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (44.55 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/hu/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (47.74 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/mt/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (20.17 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/nl/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (20.29 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/no/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_no.pdf)

polski (PL) (49.37 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/pl/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_pl.pdf)

português (PT) (20 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/pt/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_pt.pdf)

română (RO) (54.91 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/ro/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.34 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/sk/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (36.71 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/sl/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.06 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/fi/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (20.19 KB - PDF)

**First published:**

25/11/2013

**Last updated:**

07/09/2017

[View](/sv/documents/all-authorised-presentations/fortacin-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Fortacin Active substance

- lidocaine
- prilocaine

International non-proprietary name (INN) or common name

- lidocaine
- prilocaine

Therapeutic area (MeSH) Sexual Dysfunction, Physiological Anatomical therapeutic chemical (ATC) code N01BB20

### Pharmacotherapeutic group

Anesthetics

### Therapeutic indication

Treatment of primary premature ejaculation in adult men.

## Authorisation details

EMA product number EMEA/H/C/002693 Marketing authorisation holder

Recordati Ireland Ltd.

Raheens East

Opinion adopted 19/09/2013 Marketing authorisation issued 15/11/2013 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Fortacin : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (150.76 KB - PDF)

**First published:** 08/12/2014

**Last updated:** 03/02/2025

[View](/en/documents/procedural-steps-after/fortacin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Fortacin-H-C-2693-II-0030 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/418487/2020

English (EN) (405.4 KB - PDF)

**First published:** 19/10/2020

[View](/en/documents/variation-report/fortacin-h-c-2693-ii-0030-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Fortacin (II-30)

Adopted

Reference Number: EMA/CHMP/112785/2020

English (EN) (130.53 KB - PDF)

**First published:** 24/07/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-fortacin-ii-30_en.pdf)

## Initial marketing authorisation documents

Lidocaine/Prilocaine Plethora : EPAR - Public assessment report

Adopted

English (EN) (3.47 MB - PDF)

**First published:** 25/11/2013

**Last updated:** 25/11/2013

[View](/en/documents/assessment-report/lidocaineprilocaine-plethora-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Lidocaine/Prilocaine Plethora

Adopted

Reference Number: EMA/CHMP/488493/2013

English (EN) (70.01 KB - PDF)

**First published:** 20/09/2013

**Last updated:** 20/09/2013

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-lidocaineprilocaine-plethora_en.pdf)

#### News on Fortacin

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2020) 24/07/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2013) 20/09/2013

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 03/02/2025

## Share this page

[Back to top](#main-content)